Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors

Schallenberg, Simon; Plage, Henning; Hofbauer, Sebastian; Furlano, Kira; Weinberger, Sarah; Bruch, Paul Giacomo; Roßner, Florian; Elezkurtaj, Sefer; Kluth, Martina; Lennartz, Maximilian; Blessin, Niclas C.; Marx, Andreas H.; Samtleben, Henrik; Fisch, Margit; Rink, Michael; Slojewski, Marcin; Kaczmarek, Krystian; Ecke, Thorsten; Hallmann, Steffen; Koch, Stefan; Adamini, Nico; Minner, Sarah; Simon, Ronald; Sauter, Guido; Horst, David; Klatte, Tobias; Schlomm, Thorsten; Zecha, Henrik

doi:10.1080/0284186x.2023.2277344

Cited by 1 publication

(1 citation statement)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A centralized review of the cases was not done. Data on p53 immunostaining were available from a previous study [ 23 ]. The tissues were fixed in 4% buffered formalin and then embedded in paraffin.…”

Section: Methodsmentioning

confidence: 99%

PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors

Plage,

Furlano,

Hofbauer

et al. 2024

BMC Urol

Self Cite

View full text Add to dashboard Cite

Background A high level of PD-L1 expression is the most relevant predictive parameter for response to immune checkpoint inhibitor (CPI) therapy in urinary bladder cancer. Existing data on the relationship between PD-L1 expression and the natural course of disease are controversial and sparse. Methods To expand our understanding of the relationship between PD-L1 expression and parameters of cancer aggressiveness, PD-L1 was analyzed on tissue microarrays containing 2710 urothelial bladder carcinomas including 512 patients with follow-up data who underwent radical cystectomy and follow-up therapies in the pre-immune checkpoint inhibitor therapy era. Results Tumor cell positivity in ≥10% of cells were seen in 513 (20%) and an immune cell positivity occurred in 872 (34%) of 2566 interpretable cancers. PD-L1 positivity in tumor cells increased from pTaG2 low grade (0.9% positive) to pTaG3 high grade (4.1%; p = 0.0255) and was even higher in muscle-invasive (pT2–4) carcinomas (29.3%; p < 0.0001). However, within pT2–4 carcinomas, PD-L1 positivity was linked to low pT stage (p = 0.0028), pN0 (p < 0.0001), L0 status (p = 0.0005), and a better prognosis within 512 patients with cystectomy who never received CPIs (p = 0.0073 for tumor cells and p = 0.0086 for inflammatory cells). PD-L1 staining in inflammatory cells was significantly linked to PD-L1 staining in tumor cells (p < 0.0001) and both were linked to a positive p53 immunostaining (p < 0.0001). Conclusion It cannot be fully excluded that the strong statistical link between PD-L1 status and favorable histological tumor features as well as better prognosis could influence the outcome of studies evaluating CPIs in muscle-invasive urothelial carcinoma.

show abstract

Section: Methodsmentioning

confidence: 99%